In adults, the pharmacokinetics of the two individual components of co-trimoxazole are reported to be the same, whether given separately or in combination.3 Although limited pharmacokinetic data exists for trimethoprim in combination with sulphamethoxazole in children,'6 there is no available information on its kinetics when given alone. We report a study to determine the kinetics of a commonly used dosage of trimethoprim.
The combination of trimethoprim and sulphamethoxazole (co-trimoxazole) has been widely used for the treatment of urinary tract infection for many years: more recently, trimethoprim alone has been used. From published reports, there seems to be an increasing use of short courses of antibiotics for the treatment and prophylaxis of certain infectionsl and trimethoprim has been used successfully as a single drug, single dose treatment of urinary tract infection. 2 In adults, the pharmacokinetics of the two individual components of co-trimoxazole are reported to be the same, whether given separately or in combination.3 Although limited pharmacokinetic data exists for trimethoprim in combination with sulphamethoxazole in children,'6 there is no available information on its kinetics when given alone. We report a study to determine the kinetics of a commonly used dosage of trimethoprim.
Methods
Patients and protocol. Eighteen otherwise healthy children with urinary tract infections were included in the study: ethical approval had been obtained from the local research ethical committee. All children were subsequently studied and none were shown to have evidence of renal insufficiency. Their ages ranged from 3 months to 13 years, and their age, sex, and weight are shown in Table 1 .
Each child received a 10 mg/kg oral dose of trimethoprim suspension (Ipral -Squibb 50 mg per 5 ml) accurately measured by syringe. The children were in varying states of fasting and no attempt was made to standardise for meal times or meal content, although none had received a meal within two hours of drug administration. A variable volume of water or juice was given after the dose.
Capillary blood samples for plasma were collected before dosage and at one, two, three, six, 12, 18, and 24 hours afterwards. All urine passed was collected at four hourly intervals for 24 hours as 0-4, 4-8, 8-12, 12-16, 16-20, and 20-24 hour collections.
Assay preparation and technique. Aliquots of urine were diluted 10 fold and 1000 fold in 0-02 M phosphate buffer pH 7-0, and stored at 4°C until assay. After separation, plasma samples were stored at -20°C. Before assay, sera were diluted in antibiotic free horse serum. Plasma collected in the six hours after dosing was diluted 1/30 and later samples were diluted 1/5. Assays were performed within 48 hours of sampling.
Trimethoprim concentrations were determined by a bioassay method using Bacillus pumilis as the assay organism. A suspension of B pumilis spores was prepared in advance of the study and contained between 106 and 107 spores per ml. Aliquots of 0-5 ml were stored at -20°C. The medium used was Isosensitest agar (Oxoid) which was steamed to prevent production of inhibitory substances. An 'overlay' method was used to prepare the assay plates. Isosensitest agar (3-2 g in 100 ml of distilled water) was cooled to 56°C after steaming. An aliquot of spores was added and the temperature maintained for 30 minutes to 'heat shock' the spores. Five ml lysed horse blood and 1 ml of 1% para aminobenzoic acid were added, the medium mixed and poured into pre-levelled 25 cm square plates. After the base layer had solidified, an 
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Where D is the dose given (mg/kg) and F the fraction of dose which reaches the systemic circulation assumed from previous reports to be 100% of 1.8 The apparent volume of distribution (Vd) was then calculated from the relation:
The amount of trimethoprim in each four hour urine sample was the product of concentration and volume.
The trimethoprim elimination rate constant (k,1) was also derived from the slope of the least squares regression line of best fit to the plot of the logarithm of urine excretion rate against time, using combined (1) (t-450) (15-S30) (1(b64(0) (1 2-42(1) (((-236(1) squares regression analysis was 0-551 (t=5-026;
half life of 7-9 hours. The intercept on the log urine drug excretion rate axis was 7-24 mg/hour and from equation (6), the renal excretion rate constant (k.) was 0-035/hour. The mean fraction of dose excreted unchanged as calculated from equation (7) was 0035/0-108 or 0-33.
Discussion
The results show that trimethoprim is rapidly absorbed from suspension (Ipral). Trimethoprim was rapidly cleared from the body in this group of children with a mean total clearance rate of 0.241/kg/hour; approximately three times faster than rates reported in adults.9 12 As renal clearance by glomerular filtration and tubular secretion in children is not generally more efficient for other drugs that are mainly dependent upon the kidney for elimination, the results suggest that trimethoprim is eliminated by extrarenal mechanisms to a greater extent in children, presumably as a result of enhanced hepatic metabolism. Although it is commonly accepted that trimethoprim is almost completely excreted by the kidney, unchanged or as metabolites, 13 and less than 4% of a dose is present in faeces,8 the amounts of unchanged drug excreted in urine have varied in reports from 50 to 75%.9 The lower mean fraction of drug excreted in our children, 0-33, and that recovered in the urine in the first 24 hours, 0-34, supports the explanation of enhanced extrarenal elimination in children. As many drugs dependent upon these hepatic microsomal enzymes for biotransformation are eliminated at appreciably greater rates in children after the first few months of life than in adults, 14 a greater proportion of trimethoprim metabolism of the dose given to children might be expected.
This metabolism preference may prevent trimethoprim accumulation in children with renal insufficiency. Although 'usual' doses are reported to be safe in adults with a renal clearance of 10 ml/minute, most published reports suggest that the rate of trimethoprim elimination is significantly affected at or below this figure.9 "1 It may be that dose modification is unnecessary in children with lower surface area-corrected values than this. The total body trimethoprim clearance rate is so much greater in children that the mean elimination half life for plasma, 6-8 hours, is considerably shorter than values of 7 to 17 hours in adults,9 even though the mean volume of distribution is twice as large in children. The relatively short half life and rapid absorption rate suggests that during multiple dosing at usually employed 12 hour dose intervals, the fluctuation of plasma concentration may result in values below the minimum inhibitory concentration for common pathogens at sites other than the urinary tract. We know that the free concentration of antibiotics in tissues is in equilibrium with the free plasma value and the effect of such subminimum inhibitory concentrations on treatment outcome is uncertain. The high persistent concentrations achieved in urine in this single dose study suggests, however, that 12 hourly dosing is appropriate when multiple dose treatment for urinary tract infection is indicated.
Interestingly, and perhaps reassuringly, the mean elimination half life calculated from the combined urine data in this study, 7-9 hours, was similar to that derived from the individual plasma data, 6-8 hours.
Minimum inhibitory concentration for trimethoprim against Escherichia coli, klebsiella, enterobacter, and proteus range from below 1-0 mg/i to 4 mg/l. Urine trimethoprim concentrations considerably in excess of these values were rapidly achieved and maintained in all but two of the children (patients 4 and 7).
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